BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/16/2024 8:03:14 AM | Browse: 197 | Download: 850
 |
Received |
|
2024-06-23 13:31 |
|
Peer-Review Started |
|
2024-06-23 13:31 |
|
First Decision by Editorial Office Director |
|
2024-07-09 02:49 |
|
Return for Revision |
|
2024-07-09 12:53 |
|
Revised |
|
2024-07-18 12:57 |
|
Publication Fee Transferred |
|
2024-07-28 12:50 |
|
Second Decision by Editor |
|
2024-07-24 02:36 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-07-24 08:03 |
|
Articles in Press |
|
2024-07-24 08:03 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-08-12 07:33 |
|
Publish the Manuscript Online |
|
2024-08-16 08:03 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Effect and safety of ripretinib in the treatment of advanced gastrointestinal stromal tumor: A systematic review and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ji Li, Hao Zhang and Xiao-Dong Chen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xiao-Dong Chen, MS, Doctor, Doctor, Master's Student, Department of General Surgery, Chongqing Western Hospital, No. 301 Huafu Road, Jiulongpo, Chongqing 400051, China. 236165437@qq.com |
| Key Words |
Gastrointestinal stromal tumor; Ripretinib; PDGFRA; KIT; Meta-analysis |
| Core Tip |
The current therapeutic drugs have limited effectiveness in treating secondary mutations in different gastrointestinal stromal tumor (GIST), and new treatment strategies need to be developed. Ripretinib (RPT) is a new, switch-control tyrosine kinase inhibitors that can suppress different mutations of KIT and PDGFRA via a dual mechanism of action. This study aims to investigate the literature on RPT to assess an effective, safe, and successful treatment strategy against advanced GIST. |
| Publish Date |
2024-08-16 08:03 |
| Citation |
Li J, Zhang H, Chen XD. Effect and safety of ripretinib in the treatment of advanced gastrointestinal stromal tumor: A systematic review and meta-analysis. World J Clin Oncol 2024; 15(8): 1092-1101 |
| URL |
https://www.wjgnet.com/2218-4333/full/v15/i8/1092.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v15.i8.1092 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
